Salbutamol dry-powder inhalation - Acerus Pharmaceuticals

Drug Profile

Salbutamol dry-powder inhalation - Acerus Pharmaceuticals

Alternative Names: Albuterol dry-powder inhalation - Acerus Pharmaceuticals; Albuterol sulfate; Albuterol sulfate DPI; Albuterol sulfate DPI - Acerus Pharmaceuticals; Albuterol sulfate dry-powder inhalation - Acerus Pharmaceuticals; TBS-7

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trimel Biopharma
  • Developer Acerus Pharmaceuticals Corporation
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 09 Mar 2018 Acerus withdraws a phase II trial in Asthma prior to enrolment in USA (NCT01252758)
  • 17 Apr 2016 Biomarkers information updated
  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top